title: Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension?
abstract: Calcium channel blockers (CCBs) are widely used to control hypertension. Previous work suggested that their use could increase heart failure (HF), which is 1 of the consequences of uncontrolled hypertension. Information about the effect of CCBs on incident HF in patients with hypertension is scarce. A systematic review was conducted to evaluate patients with hypertension treated with CCBs and incident HF. An electronic search of publications was conducted using 8 major databases. Studies were eligible if they (1) were randomized clinical trials, (2) performed comparisons of CCBs versus active control, (3) randomized >200 patients, (4) had follow-up periods >6 months, and (5) provided data regarding incident HF. Trials of renal transplantation patients, placebo-controlled trials, and HF trials were excluded. A total of 156,766 patients were randomized to CCBs or control, with a total of 5,049 events. The analysis indicated a significant increase in the diagnosis of HF in patients allocated to CCBs (odds ratio 1.18, 95% confidence interval 1.07 to 1.31). The effect observed was independent of incident myocardial infarction. Subgroup analyses indicated that patients with diabetes were at higher risk for developing HF (odds ratio 1.71, 95% confidence interval 1.21 to 2.41). In conclusion, the results suggest that patients with hypertension treated with CCBs have increased incident HF.
authors.affiliation: EPICORE Centre, Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. marcelo.shibata@ualberta.ca
authors.forename: Marcelo C
authors.initials: MC
authors.lastname: Shibata
authors.forename: Hernando
authors.initials: H
authors.lastname: León
authors.forename: Trish
authors.initials: T
authors.lastname: Chatterley
authors.forename: Marlene
authors.initials: M
authors.lastname: Dorgan
authors.forename: Ben
authors.initials: B
authors.lastname: Vandermeer
mesh_terms: D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D015994:Incidence; D008297:Male
chemical_list: D002121:Calcium Channel Blockers